Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat HCC, such as targeted tyrosine kinase inhibitors, immune based therapies and combination of chemotherapy. However, limitation...
Saved in:
Main Authors: | Danyu Du (Author), Chan Liu (Author), Mengyao Qin (Author), Xiao Zhang (Author), Tao Xi (Author), Shengtao Yuan (Author), Haiping Hao (Author), Jing Xiong (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dysregulated transmethylation leading to hepatocellular carcinoma compromises redox homeostasis and glucose formation
by: Curtis C. Hughey, et al.
Published: (2019) -
Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
by: Lei Jiang, et al.
Published: (2023) -
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
by: Xin Qing, et al.
Published: (2021) -
Development and novel therapeutics in hepatocellular carcinoma: a review
by: Ingle PV, et al.
Published: (2016) -
Application of nanotechnology in the treatment of hepatocellular carcinoma
by: Liu Cai, et al.
Published: (2024)